Martin Grumet

Martin Grumet

(848) 445-6577
(732) 445-2063
D251 Nelson Labs
Mesenchymal Stem Cells (MSC) as Anti-Inflammatory Therapies

B.S., The Cooper Union, New York, NY
Ph.D., The Johns Hopkins University, Baltimore, MD.

Postdoctoral Training, Dr. Gerald M. Edelman Advisor, The Rockefeller University, New York, NY

Assistant Professor, The Rockefeller University, New York, NY
Associate Professor, NYU Medical Center, New York, NY

NIH Graduate Fellowship, Johns Hopkins University
NIH Post Doctoral Fellowship, Rockefeller University
Irma T. Hirschl Career Scientist Award

Neural stem cells in development & neurological disorders

Translational Studies on Mesenchymal Stem Cells (MSC)

Our lab is now studying clinical trials using mesenchymal stem cell (MSC) that are listed in, the most widely used and respected database worldwide. In the past several years we have performed an analysis of >1,000 such trial and reported in Stem Cell Translational Medicine in 2020 on a range of intravenous doses (70-190 million cells/dose) that we defined as minimal effective doses based on published data. We are currently continuing these studies with a focus on COVID-19 and found that several studies are using doses lower doses that we suggested. Additional studies are in progress for diseases of the CNS. We have also invented a system for rapid scaleup of encapsulated MSC. These are advantageous because they survive for months in vivo rather than for days by comparison to free MSC. We are searching for commercial partners producing MSC for translational studies of encapsulated MSC.

For CBN's main publication search, click here.

Studies of stem cells in clinical trials
Email with CV

Fall: Yes
Spring: Yes
Summer: Yes

Interest in stem cell and/or clinical trials